Petition Against Increlex Approval Not "Compelling" – Agency Review
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Insmed's contention that Tercica's orphan drug Increlex lacked an adequate safety database to justify approval was contradicted by the "very large" amount of data relative to the size of the target population, according to Office of Drug Evaluation II Director Robert Meyer, MD